Pharma News


About Authors:
Sandhu Premjeet1, 2,Rathore Devashish2, Kataria Sahil1 , Middha Akanksh1
1Seth G. L. Bihani S.D. College of Technical Education,
Institute of Pharmaceutical Sciences and Drug Research,
Sri Ganganagar, Rajasthan, INDIA
2 School of Pharmaceutical Sciences, RGPV University campus,
Bhopal, M.P, INDIA

The blood – brain barrier (BBB) has always presented a challenge to scientists for brain drug targeting . the BBB evolved in such a way that it protects the brain from various foreign substance such as neurotoxins. This mechanism makes the BBB an insurmountable . This mechanism makes BBB an insurmountable barrier for numerous highly essential drugs , including antibiotics, cytostatics and other CNS active drug Drugs may be administered directly into the CNS or administered systematically (e.g. by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance. Various strategies that have been used for manipulating the blood-brain barrier for drug delivery to the brain include osmotic and chemical opening of the blood-brain barrier as well as the use of transport/carrier systems. Other strategies for drug delivery to the brain involve bypassing the BBB. Various pharmacological agents have been used to open the BBB and direct invasive methods can introduce therapeutic agents into the brain substance. It is important to consider not only the net delivery of the agent to the CNS, but also the ability of the agent to access the relevant target site within the CNS. Various routes of administration as well as conjugations of drugs, e.g. with liposomes and nanoparticles are considered. Some routes of direct administration to the brain are non-invasive such as transnasal route whereas others involve entry into the CNS by devices and needles such as in case of intrathecal and intracerebroventricular delivery.

Transdermal Drug Delivery System- A Total View

About Authors:
Vinay Mishra, Shilpi Bhargava
Advance Institute of Biotech and Paramedical Sciences,

Delivering medicine to the general circulation through the skin is seen as a desirable alternative to taking it by mouth. Patientsoften forget to take their medicine, and even the most faithfullycompliant get tired of swallowing pills, especially if theymust take several each day. Additionally, bypassing the gastrointestinal(GI) tract would obviate the GI irritation that frequently occursand avoid partial first-pass inactivation by the liver. Further,steady absorption of drug over hours or days is usually preferableto the blood level spikes and troughs produced by oral dosageforms.1

Isolation And Molecular Characterization Of Xylanase Enzyme From Soil

About Author:
Microbiologist  In  Institute Of Health Systems, Hyderabad
M.Sc Microbiology From Osmania University.

The purpose of this study was to determine the effect of some cultural conditions on the xylanase enzyme production by two Isolated Species from the industrial soiland to investigate its potential to produce xylanase utilizing tomato pomace as a substrate. Xylanase activity was detected using the Dinitrosalicylic acid assay method.
The Alkalophilic bacteria isolated from the industrial soil, secreats extra cellular xylanases when grown in liquid media supplemented with eighter rice bran, grass, corn cob, or sugar baggage as a carbon sources (which were treated with 2N NaoH for removing the cellulose from these substrates). The two bacteria belonging to the species Sporo lactobacilli and Acrobacter respectively shows the high enzyme activity at high temperatures 50?C and 60?C and high enzyme activity was found at pH 8 and pH 9 for two organisms. The extra cellular enzyme has an apparent molecular weight of 66 KD & 67KD for both the organism respectively, as determined by SDS-PAGE. The purified enzyme has two peptides and was conformed by Zymogram analysis. The species sporo lactobacilli show high enzyme activity of 4.7 U/ml and the species Acrobacter shows the enzyme activity of 7.46 U/ml.

Farewell time for world’s largest selling chartbuster pharmaceutical brand Lipitor®: What next after November 30, 2011

About Authors:
Dr. Amit Gangwal,
Smriti College of Pharmaceutical Education,

Lipitor® is the best-selling drug ever, accounting for $106 billion sales over the last decade. Two generic drug manufacturers are ready to compete starting December 1, 2011. Watson Pharmaceuticals is making a generic version authorized by Pfizer under a profit-sharing agreement. Pending federal approval, Ranbaxy Laboratories also plans to sell a generic version. It is noteworthy that when a drug’s patent protection expires, the federal law permits only limited generic competition in the first six months1.

AstraZeneca announced Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)

AstraZeneca announced top-line results from SATURN. SATURN was designed to measure the impact of CRESTOR (rosuvastatin) 40 mg and atorvastatin 80 mg on the progression of atherosclerosis in high risk patients.

New Studies suggests " which is more relevant to reduce risk of venous thromboembolism: Estradiol transdermal system or estrogen contraceptive pills "

A New studies suggested a new hormonal therapy to reduce risk of venous thromboembolism than oral estrogen-only hormone therapy agents (contraceptive pills). In this study they compared Estradiol transdermal system with oral estrogen hormone therapy.